Tolley was initiated in 2008 by health economist, Keith Tolley, and scientist, Mandy Strickson, to offer pharmaceutical and biotech clients a caring and bespoke approach to their health technology assessment (HTA) needs.
With three decades of experience from ‘three sides of the fence’
(academia, pharma, and consultancy), Keith and Mandy wanted to create a team of Health Economists and HTA Evidence Analysts that aligned with their ethos of “small is beautiful” and to perform projects to support evidence generation needs and to prepare the value case for UK and RoI HTA submissions.
Our focus
Our focus is on the demonstration of the relative clinical and cost-effectiveness of new pharmaceuticals. Our wealth and experience ensures high quality with an emphasis on the strategic assessment needs for HTA.
Our vision
Our vision is to offer pharmaceutical and biotech companies bespoke consultancy on all aspects for HTA, culminating in patients gaining access to new and innovative treatments.
Our mission
Our mission is to provide bespoke, high quality work and form long-lasting client relationships to uphold and build on our valued reputation.
Our approach
to the evidence required to fulfill robust submissions…
Latest success stories
NICE recommend...
…the first therapy to treat epidermolysis bullosa (EB)